Baragaño Raneros Aroa, López-Larrea Carlos, Suárez-Álvarez Beatriz
Translational Immunology Laboratory, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Hospital Universitario Central de Asturias, Oviedo, Spain.
Immunology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.
Oncoimmunology. 2018 Oct 31;8(2):e1539617. doi: 10.1080/2162402X.2018.1539617. eCollection 2019.
Acute myeloid leukemia (AML) is a heterogeneous disease whose therapies currently show elevated toxicity and a high rate of relapse. Recently, the burgeoning of new anti-tumor therapeutic strategies aimed at enhancing the immune response has pushed natural killer cells (NKs) into the spotlight. These cells are powerful warriors that can bring about the lysis of tumor cells through their cytotoxic ability. However, tumor cells have developed strategies to evade recognition mediated by NKs. Here, we review the mechanisms triggered by AML cells and discuss the emerging immunotherapeutic strategies that potentiate the anti-tumor functions of NKs.
急性髓系白血病（AML）是一种异质性疾病，其现有治疗方法目前显示出较高的毒性和复发率。最近，旨在增强免疫反应的新型抗肿瘤治疗策略的兴起，使自然杀伤细胞（NK细胞）成为焦点。这些细胞是强大的战士，能够通过其细胞毒性能力使肿瘤细胞裂解。然而，肿瘤细胞已经发展出逃避NK细胞介导的识别的策略。在此，我们综述了AML细胞触发的机制，并讨论了增强NK细胞抗肿瘤功能的新兴免疫治疗策略。
